Moffitt Cancer Center launched a clinical trial testing a form of immunotherapy in place of chemotherapy for certain breast cancer cases. The trial targets HER2-positive breast cancer patients with ...

The US Food and Drug Administration recently approved an alternative treatment option for patients with BCG-unresponsive high ...

A genetic switch that activates immune cells as they fight tumors: this is the new strategy developed by an international ...

The FDA expanded approval of Anktiva for bladder cancer. The agent is the first approved treatment for BCG-unresponsive, high ...

A 2023 review from Fudan University documents how Chinese clinical trials and single-cell omics studies are transforming the ...

Immorta Bio, Inc., a biotechnology company pioneering therapies targeting fundamental mechanisms of aging, today announced ...

Two patients receive the same immunotherapy for the same cancer. In one, the tumor retreats and stays gone for years. In the other, the treatment does nothing. Oncologists still have no reliable way ...

Colorectal cancer has become the leading cause of cancer-related death for people under 50. Its most common forms generally aren't treatable, either through conventional means like chemotherapy or ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

High-risk neuroblastoma is one of the most aggressive forms of solid tumors affecting children, originating in the nervous ...

Since I started sublingual immunotherapy in June 2025 with the goal of eradicating my cedar pollen allergy, my first cedar ...